Chugai has announced that ACE910, inhibits blood factor VIII in people aged 12 years or older and results have been designated by US FDA as a breakthrough therapy for the treatment of hemophilia A. ACE910 is a bispecific antibody created by Chugai’s proprietary antibody engineering technologies for the purpose of mimicking the function of blood coagulation factor VIII.
Chugai press release, September 4, 2015
Chugai develops antibody for hemophilia A treatment